Drugs / TRX518
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03861403 | May 2019 → Jul 2020 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Leap Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02628574 | Jan 2016 → Jul 2020 | cancer | Leap Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01239134 | Oct 2010 → Sep 2018 | metastatic melanoma | Leap Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRX518 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02628574 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 18 agonist” CHEMBL2109428 ↗1“GITR agonism” PMID 31036879 ↗ Apr 2019 |
| Modality | Monoclonal antibody | “Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody” NCT01239134 ↗ |
| Route | Intravenous | “TRX518 will be given IV over 1 hour” NCT01239134 ↗ |
| Target | TNFRSF18 | “Tumor necrosis factor receptor superfamily member 18 agonist” CHEMBL2109428 ↗ |